MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on October 30, 2007; DOI: 10.1124/mol.107.041640


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.107.041640v1
73/2/305    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hussainzada, N.
Right arrow Articles by Swaan, P. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hussainzada, N.
Right arrow Articles by Swaan, P. W.


Received for publication September 7, 2007.
Revised October 22, 2007.
Accepted for publication October 29, 2007.

Conformational Flexibility of Helix VI is Essential for Substrate Permeation of the Human Apical Sodium-dependent Bile Acid Transporter (ASBT)

Naissan Hussainzada 1, Akash Khandelwal 1, Peter W. Swaan 1*

1 University of Maryland

* Address correspondence to: E-mail: pswaan{at}rx.umaryland.edu

Abstract

The present study characterizes the methanethiosulfonate (MTS) inhibition profiles of 26 consecutive cysteine-substituted mutants comprising transmembrane (TM) helix 6 of the human apical Na+-dependent bile acid transporter (hASBT, SLC10A2). TM6 is linked exofacially to TM7 via extracellular loop (EL) 3. TM7 was previously identified as lining part of the substrate permeation path (Hussainzada et al. Mol Pharmacol 70:1565, 2006). Most TM6 cysteine replacements were well-tolerated, except for five residues with either severely hampered (I229C, G249C) or abolished (P234C, G237C, G241C) activity. Disruption of protein synthesis or folding accounted for lack of activity for mutant P234C. Subsequent amino acid replacements at Pro234 demonstrate its essential nature in both structural and functional aspects of the transport cycle. Application of polar MTS reagents (1 mM) significantly inhibited activity of six mutants (V235C, S239C, F242C, R246C, A248C, Y253C), for which rates of modification were almost fully reversed (except Y253C) upon inclusion of bile acid substrates or removal of Na + from the MTS pre-incubation medium. Activity assessments at equilibrative [Na+] revealed numerous Na+ sensitive residues, suggesting their proximity in or around Na+ interaction sites. In silico modeling reveals the intimate and potentially cooperative orientation of MTS-accessible TM6 residues toward functionally important TM7 amino acids, substantiating TM6 participation during the transport cycle. We conclude a functional requirement for helical flexibility imparted by Pro234, Gly237 and Gly241, likely forming a "conformational switch" requisite for substrate turnover; meanwhile, MTS-accessible residues, which line a helical face spatially distinct from this switch, may participate during substrate permeation.


Key words: Organic anion, Structure-activity relationships and modeling, Mutagenesis/Chimeric approaches, Cholesterol metabolism/lipoproteins


This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
N. Hussainzada, T. C. Da Silva, E. Y. Zhang, and P. W. Swaan
Conserved Aspartic Acid Residues Lining the Extracellular Loop I of Sodium-coupled Bile Acid Transporter ASBT Interact with Na+ and 7{alpha}-OH Moieties on the Ligand Cholestane Skeleton
J. Biol. Chem., July 25, 2008; 283(30): 20653 - 20663.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics